Sandra Nayeli Montelongo Sevilla, in Los Angeles, CA - Counselor

Sandra Nayeli Montelongo Sevilla, is a Counselor - Mental Health based in Los Angeles, California. Sandra Nayeli Montelongo Sevilla is licensed to practice in * (Not Available) (license number ) and her current practice location is 333 S Beaudry Ave, Los Angeles, California. She can be reached at her office (for appointments etc.) via phone at (818) 993-9311.

NPI number for Sandra Nayeli Montelongo Sevilla is 1003392465 and her current mailing address is 333 S Beaudry Ave, Los Angeles, California. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1003392465.

Contact Information

	Sandra Nayeli Montelongo Sevilla,
	333 S Beaudry Ave, Los Angeles, CA 90017-1466
	(818) 993-9311
	Not Available

Healthcare Provider's Profile

Full Name	Sandra Nayeli Montelongo Sevilla
Gender	Female
Speciality	Counselor - Mental Health
Location	333 S Beaudry Ave, Los Angeles, California
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1003392465
Provider Enumeration Date: 07/18/2018
Last Update Date: 06/09/2023

Medical Identifiers

Medical identifiers for Sandra Nayeli Montelongo Sevilla such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1003392465	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
1041C0700X	Social Worker - Clinical	ACSW95362 (California)	Secondary
1041C0700X	Social Worker - Clinical	95362 (California)	Secondary
390200000X	Student In An Organized Health Care Education/training Program	(* (Not Available))	Secondary
101YM0800X	Counselor - Mental Health	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Sandra Nayeli Montelongo Sevilla is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Sandra Nayeli Montelongo Sevilla, 333 S Beaudry Ave, Los Angeles, CA 90017-1466 Ph: (818) 993-9311	Sandra Nayeli Montelongo Sevilla, 333 S Beaudry Ave, Los Angeles, CA 90017-1466 Ph: (818) 993-9311

News Archive

JDRF initiates enrollment in metformin clinical study for type 1 diabetes

JDRF-funded researchers have begun enrolling adult patients with type 1 diabetes (T1D) in the REMOVAL study, to test whether metformin-a drug commonly used to treat type 2 diabetes-could help prevent or reduce the risk of cardiovascular complications in people with T1D.

Persistant industrial chemical modifies gut microbiome of mice

An industrial chemical - phased out since 2002, but previously used in stain and water-repellent products and firefighting foam - alters the gut microbiome of mice and could have implications for human health, according to an international team of researchers.

Low energy diet improves obstructive sleep apnoea in obese men

Weight loss reduces obstructive sleep apnoea in obese men, with the greatest effect seen in patients with severe disease, according to new research published on bmj.com today.

Focal choroidal excavation's coexistence with other choroidal diseases impairs vision

Focal choroidal excavation appears to be relatively common and can have a detrimental effect on vision, a study of Korean patients suggests.

Halozyme Therapeutics granted U.S. patent for recombinant human hyaluronidase enzyme platform

Halozyme Therapeutics, Inc. today announced the issuance of U.S. Patent No. 7,767,429 claiming its proprietary recombinant human hyaluronidase enzyme platform (rHuPH20). Claims to the human PH20 glycoprotein, PEGylated variants, the glycoprotein produced by recombinant methods, and pharmaceutical compositions with other agents, including antibodies, insulins, cytokines, anti-infectives and additional therapeutic classes were awarded in the '429 patent. Additional claims are in prosecution.

Sandra Nayeli Montelongo Sevilla, - in Los Angeles, CA